『You’re Missing the Biggest GLP-1 Benefit (And It’s NOT Weight Loss)』のカバーアート

You’re Missing the Biggest GLP-1 Benefit (And It’s NOT Weight Loss)

You’re Missing the Biggest GLP-1 Benefit (And It’s NOT Weight Loss)

無料で聴く

ポッドキャストの詳細を見る

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
#GLP1 #Ozempic #Mounjaro #Wegovy #ObesityMedicineMost people think GLP-1 medications like Ozempic, Wegovy, Mounjaro and Zepbound are just for weight loss. The research tells a much bigger story. I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine, with more than 15 years as a hospitalist. In this video I count down 12 evidence-graded health benefits of GLP-1 medications beyond the scale, plus a bonus from the newest cancer research.You'll learn what the major trials show about your heart, liver, kidneys, blood pressure, sleep apnea, inflammation, alcohol cravings, joint pain and blood sugar. I also cover what the latest Alzheimer's trials actually found. Stay for number 1: a major analysis of the SELECT trial found that about two-thirds of the heart protection wasn't explained by weight loss.📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.comTIMESTAMPS0:00 Why GLP-1s are about more than weight loss1:05 Who I am and why this matters1:56 #12 Blood pressure and blood fats2:42 #11 Less joint pain, more mobility3:52 #10 Fewer alcohol cravings5:00 #9 A healthier liver5:50 #8 Brain health: the honest version6:55 How to protect muscle on a GLP-1 + Masterclass8:42 #7 Sleep apnea and deeper sleep9:40 #6 Fewer medications and diabetes prevention10:35 BONUS: GLP-1s and cancer, the newest research11:38 Free GLP-1 Diet Cookbook12:03 #5 Quieter food noise and steadier blood sugar12:57 #4 Protecting your kidneys13:46 #3 Blood sugar and diabetes control14:35 #2 Cooling down inflammation15:27 #1 Protecting your heart and blood vesselsREFERENCESDeanfield J, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements (SELECT analysis). Lancet. 2025. PMID: 41138739Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure. Lancet. 2021;397:1625-1636Bliddal H, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis (STEP 9). N Engl J Med. 2024;391:1573-1583Eli Lilly. Retatrutide TRIUMPH-4 topline results (press release, Dec 11, 2025; not yet peer-reviewed). https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-averageKosiborod MN, et al. Semaglutide in HFpEF and obesity (STEP-HFpEF). N Engl J Med. 2023;389:1069-1084Hendershot CS, et al. Once-weekly semaglutide in adults with alcohol use disorder. JAMA Psychiatry. 2025;82(4):395-405Klausen MK, et al. Once-weekly semaglutide vs placebo in alcohol use disorder and comorbid obesity. Lancet. 2026. PMID: 42070571Younossi ZM, et al. The global epidemiology of NAFLD and NASH. Hepatology. 2023;77(4):1335-1347Sanyal AJ, et al. Phase 3 trial of semaglutide in MASH (ESSENCE). N Engl J Med. 2025;392:2089-2099Wang W, et al. Semaglutide and first-time diagnosis of Alzheimer's disease in type 2 diabetes. Alzheimers Dement. 2024;20(12):8661-8672evoke and evoke+ Investigators. Oral semaglutide in early-stage symptomatic Alzheimer's disease. Lancet. 2026Lundgren JR, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined (S-LITE). N Engl J Med. 2021;384:1719-1730Heymsfield SB, Aronne LJ, et al. Bimagrumab plus semaglutide for obesity (BELIEVE). Nat Med. 2026. https://www.nature.com/articles/s41591-026-04204-0Malhotra A, et al. Tirzepatide for obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391:1193-1205Jastreboff AM, et al. Tirzepatide for obesity treatment and diabetes prevention (SURMOUNT-1, 3 years). N Engl J Med. 2025;392:958-971Lauby-Secretan B, et al. Body fatness and cancer — viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794-798(complete list available upon request)⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません